SOURCE: Serenex

January 24, 2008 10:07 ET

Serenex Announces Collaboration With National Cancer Institute to Evaluate Proprietary Small Molecule Hsp90 Inhibitors as a Potential Treatment for Lung Cancer

DURHAM, NC--(Marketwire - January 24, 2008) - Serenex, Inc., a leader in the discovery and development of small molecule Heat Shock Protein 90 (Hsp90) inhibitors, today announced the signing of a Materials Cooperative Research and Development Agreement (M-CRADA) with the National Cancer Institute (NCI) at the National Institutes of Health (NIH). Under this M-CRADA, Dr. Leonard Neckers and his colleagues at the NCI will assess Serenex's novel, small molecule, orally bioavailable Hsp90 inhibitor SNX-5422 as a potential therapeutic for non-small cell lung cancer.

"In preclinical studies SNX-5422 has shown exceptional efficacy in multiple xenograft models including lung cancer," said Richard Kent, M.D., president and chief executive officer of Serenex. "This important collaboration with the NCI further validates the potential of our Hsp90 Product Platform. We look forward to collaborating with Dr. Neckers to generate additional data to support initiating clinical trials in patients with lung cancer."

About Hsp90

Hsp90 is an important molecular chaperone protein that regulates the folding and stability of key signaling molecules (client proteins) involved in cell growth and survival. The central role of Hsp90 in cell growth has made it an attractive target for oncology, and currently there are several Hsp90 inhibitors in clinical development for the treatment of both solid and hematological tumors, including SNX-5422. Inhibition of Hsp90 is also an attractive drug target for Huntington's disease and other neurodegenerative diseases because a number of the proteins thought to be responsible for these diseases are either direct client proteins of Hsp90 or are downstream effectors of client proteins.

About Serenex

Serenex is an integrated drug discovery and development company and a leader in the discovery and development of small molecule Hsp90 inhibitors. Serenex has a novel small molecule inhibitor of Heat Shock Protein 90, SNX-5422, which is in phase 1 clinical trials for cancer. SNX-5422 was developed from the Company's Hsp90 Product Platform, a proprietary collection of several hundred potent small molecule Hsp90 inhibitors. Hsp90 is a central protein responsible for chaperoning a large number of oncogenic and other proteins and is believed to play a key role in cancer, inflammatory diseases, fungal infection resistance, viral diseases and neurodegenerative diseases such as Alzheimer's and Huntington's disease. Serenex has ongoing pre-clinical programs in all of these areas. Additionally, Serenex is developing SNX-1012, a product for oral mucositis in solid tumor patients scheduled to complete phase 2 clinical trials in mid-2008. Serenex's pipeline is powered by a proprietary high throughput screening platform which enables the company to profile compounds, en masse, against thousands of important therapeutic and toxicity targets. Website: www.serenex.com.

Contact Information

  • CONTACT:
    Ian Howes
    CFO & Sr. V.P. Corporate Development
    Serenex, Inc.
    919/281-6001
    Email Contact

    Michelle Linn
    Linnden Communications
    774-696-3803
    Email Contact